

Maria Luisa Brandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6578289/publications.pdf>

Version: 2024-02-01

179
papers

12,993
citations

57681

46
h-index

28425

109
g-index

202
all docs

202
docs citations

202
times ranked

13217
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant Epigenetic Alteration of <i>PAX1</i> Expression Contributes to Parathyroid Tumorigenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e783-e792.	1.8	11
2	Bone Marrow Edema. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 189-200.	1.4	8
3	Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 171-183.	2.6	21
4	Association between vitamin D and bisphenol A levels in an elderly Italian population: results from the InCHIANTI study. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
5	Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	1.8	1
6	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	1.4	33
7	Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database. <i>Endocrine Connections</i> , 2022, 11, .	0.8	1
8	Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series. <i>Endocrine</i> , 2022, , 1.	1.1	6
9	<i>ALPL</i> Genotypes in Patients With Atypical Femur Fractures or Other Biochemical and Clinical Signs of Hypophosphatasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2087-e2094.	1.8	2
10	Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on the MEN1 Florentine Database. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2110-e2123.	1.8	1
11	Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1653-1662.	1.8	5
12	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. <i>Nutrients</i> , 2022, 14, 1742.	1.7	8
13	Circulating MicroRNAs as Biomarkers of Osteoporosis and Fragility Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2267-2285.	1.8	10
14	Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data. <i>Nutrients</i> , 2022, 14, 2369.	1.7	4
15	Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. <i>Osteoporosis International</i> , 2022, 33, 2467-2478.	1.3	9
16	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome – An International Consensus Statement. <i>Neuroendocrinology</i> , 2021, 111, 609-630.	1.2	63
17	Edema-like marrow signal intensity: a narrative review with a pictorial essay. <i>Skeletal Radiology</i> , 2021, 50, 645-663.	1.2	28
18	Multiple Endocrine Neoplasia Type 1: Latest Insights. <i>Endocrine Reviews</i> , 2021, 42, 133-170.	8.9	85

#	ARTICLE	IF	CITATIONS
19	Quality of life in Italian patients with Multiple endocrine neoplasia type 1 (MEN 1): results of an extensive survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 16.	1.2	7
20	Chronic hypoparathyroidism and treatment with teriparatide. <i>Endocrine</i> , 2021, 72, 249-259.	1.1	11
21	The Involvement of Long Non-Coding RNAs in Bone. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3909.	1.8	31
22	MicroRNAs regulatory networks governing the epigenetic landscape of MEN1 gastroenteropancreatic neuroendocrine tumor: A case report. <i>Clinical and Translational Medicine</i> , 2021, 11, e351.	1.7	4
23	Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4041.	1.8	19
24	Mediterranean diet adherence and dietary calcium intake in a group of pregnant women: Results of an Italian survey. <i>Food Science and Nutrition</i> , 2021, 9, 3426-3435.	1.5	2
25	How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?. <i>Osteoporosis International</i> , 2021, 32, 1921-1935.	1.3	6
26	Skeletal System Biology and Smoke Damage: From Basic Science to Medical Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6629.	1.8	15
27	GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4084-e4096.	1.8	3
28	Polymorphic variants of alkaline phosphatase gene correlate with clinical signs of adult hypophosphatasia?. <i>Osteoporosis International</i> , 2021, 32, 2461-2472.	1.3	4
29	Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. <i>Journal of Bone Oncology</i> , 2021, 28, 100361.	1.0	14
30	Study of the Expression and Function of Calcium-Sensing Receptor in Human Skeletal Muscle. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7282.	1.8	5
31	Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. <i>Cells</i> , 2021, 10, 1895.	1.8	10
32	Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7352.	1.8	9
33	Genetic Determinants of Inherited Endocrine Tumors: Do They Have a Direct Role in Bone Metabolism Regulation and Osteoporosis?. <i>Genes</i> , 2021, 12, 1286.	1.0	1
34	MicroRNAs as Potential Biomarkers in Pituitary Adenomas. <i>Non-coding RNA</i> , 2021, 7, 55.	1.3	5
35	Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10465.	1.8	6
36	Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 295-307.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Hypoparathyroidism: State of the Art on Cell and Tissue Therapies. International Journal of Molecular Sciences, 2021, 22, 10272.	1.8	6
38	Congenital Metabolic Bone Disorders as a Cause of Bone Fragility. International Journal of Molecular Sciences, 2021, 22, 10281.	1.8	4
39	Bone fragility in patients affected by congenital diseases non skeletal in origin. Orphanet Journal of Rare Diseases, 2021, 16, 11.	1.2	4
40	Muscle Physiopathology in Parathyroid Hormone Disorders. Frontiers in Medicine, 2021, 8, 764346.	1.2	9
41	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet Journal of Rare Diseases, 2021, 16, 421.	1.2	5
42	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. Nutrients, 2021, 13, 3567.	1.7	6
43	Parathyroid Tumors: Molecular Signatures. International Journal of Molecular Sciences, 2021, 22, 11206.	1.8	11
44	The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocrine Disorders, 2021, 21, 232.	0.9	3
45	Available In Vitro Models for Human Satellite Cells from Skeletal Muscle. International Journal of Molecular Sciences, 2021, 22, 13221.	1.8	15
46	Surgical management of chordoma: A systematic review. Journal of Spinal Cord Medicine, 2020, 43, 797-812.	0.7	30
47	Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome. International Journal of Molecular Sciences, 2020, 21, 7592.	1.8	9
48	Vitamin K and Osteoporosis. Nutrients, 2020, 12, 3625.	1.7	62
49	Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. Trends in Endocrinology and Metabolism, 2020, 31, 918-927.	3.1	46
50	Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 2020, 32, 547-560.	1.4	65
51	Characterization of Skeletal Muscle Endocrine Control in an In Vitro Model of Myogenesis. Calcified Tissue International, 2020, 107, 18-30.	1.5	17
52	Blueberry Juice Antioxidants Protect Osteogenic Activity against Oxidative Stress and Improve Long-Term Activation of the Mineralization Process in Human Osteoblast-Like SaOS-2 Cells: Involvement of SIRT1. Antioxidants, 2020, 9, 125.	2.2	29
53	Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort. British Journal of Surgery, 2020, 107, 1489-1499.	0.1	28
54	Bone tissue and mineral metabolism in hereditary endocrine tumors: clinical manifestations and genetic bases. Orphanet Journal of Rare Diseases, 2020, 15, 102.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1967-1978.	3.1	32
56	Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. <i>International Journal for Vitamin and Nutrition Research</i> , 2020, 90, 200-204.	0.6	7
57	In Vitro Control of Genes Critical for Parathyroid Embryogenesis by Extracellular Calcium. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa058.	0.1	6
58	A registry for patients with chronic hypoparathyroidism in Russian adults. <i>Endocrine Connections</i> , 2020, 9, 627-636.	0.8	8
59	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2020, 27, T53-T63.	1.6	20
60	Reply to Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1413-1415.	3.1	0
61	Guidelines for the management of osteoporosis and fragility fractures. <i>Internal and Emergency Medicine</i> , 2019, 14, 85-102.	1.0	198
62	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	1.3	69
63	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019, 36, 2811-2824.	1.3	60
64	X-linked hypophosphatemic rickets: an Italian experts' opinion survey. <i>Italian Journal of Pediatrics</i> , 2019, 45, 67.	1.0	31
65	Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. <i>Calcified Tissue International</i> , 2019, 105, 271-284.	1.5	102
66	Muscle endocrinology and its relation with nutrition. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 783-792.	1.4	18
67	AB0831...PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS. , 2019, , .		0
68	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019, 180, P1-P22.	1.9	81
69	Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. <i>Osteoporosis International</i> , 2019, 30, 391-402.	1.3	56
70	Clinical Presentation of Hypoparathyroidism. <i>Frontiers of Hormone Research</i> , 2019, 51, 139-146.	1.0	9
71	Conventional Treatment of Hypoparathyroidism. <i>Frontiers of Hormone Research</i> , 2019, 51, 160-164.	1.0	5
72	A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides. <i>Frontiers of Hormone Research</i> , 2019, 51, 165-171.	1.0	6

#	ARTICLE	IF	CITATIONS
73	The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. <i>Nature Reviews Endocrinology</i> , 2019, 15, 33-51.	4.3	226
74	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. <i>European Journal of Endocrinology</i> , 2019, 180, R37-R44.	1.9	41
75	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	1.5	23
76	Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens: response to comments by Chen et al.. <i>Osteoporosis International</i> , 2018, 29, 1219-1220.	1.3	1
77	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018, 62, 215-233.	1.1	21
78	Understanding osteoporotic pain and its pharmacological treatment. <i>Osteoporosis International</i> , 2018, 29, 1477-1491.	1.3	28
79	Clinical presentation and management of patients with primary hyperparathyroidism in Italy. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1339-1348.	1.8	32
80	Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database. <i>Calcified Tissue International</i> , 2018, 103, 144-150.	1.5	20
81	MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. <i>Endocrine</i> , 2018, 59, 438-448.	1.1	33
82	Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 205.	1.2	27
83	Calcium Intake in Bone Health: A Focus on Calcium-Rich Mineral Waters. <i>Nutrients</i> , 2018, 10, 1930.	1.7	108
84	Clinical presentation and management of hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 927-939.	2.2	25
85	When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism. <i>Frontiers in Endocrinology</i> , 2018, 9, 597.	1.5	10
86	Calcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor Activity. <i>Journal of Immunology</i> , 2018, 201, 3175-3183.	0.4	12
87	Bone management in hematologic stem cell transplant recipients. <i>Osteoporosis International</i> , 2018, 29, 2597-2610.	1.3	39
88	Causes and pathophysiology of hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 909-925.	2.2	21
89	Phosphate wasting disorders in adults. <i>Osteoporosis International</i> , 2018, 29, 2369-2387.	1.3	32
90	Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation. <i>Osteoporosis International</i> , 2018, 29, 2153-2154.	1.3	6

#	ARTICLE	IF	CITATIONS
91	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 2017, 28, 767-774.	1.3	113
92	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	1.1	77
93	Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership. Archives of Osteoporosis, 2017, 12, 21.	1.0	17
94	Estrogen inhibits starvation-induced apoptosis in osteocytes by a redox-independent process involving association of JNK and glutathione S-transferase P1. FEBS Open Bio, 2017, 7, 705-718.	1.0	15
95	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	1.3	126
96	Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opinion on Drug Safety, 2017, 16, 617-625.	1.0	19
97	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.	1.1	52
98	The Epidemiology of Hypoparathyroidism in Italy: An 8-Year Register-Based Study. Calcified Tissue International, 2017, 100, 278-285.	1.5	30
99	Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporosis International, 2017, 28, 3239-3249.	1.3	31
100	Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine, 2017, 377, 1417-1427.	13.9	901
101	Protective role of benzoselenophene derivatives of resveratrol on the induced oxidative stress in intestinal myofibroblasts and osteocytes. Chemico-Biological Interactions, 2017, 275, 13-21.	1.7	14
102	The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International, 2017, 28, 447-462.	1.3	130
103	Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons. Osteoporosis International, 2017, 28, 667-675.	1.3	37
104	Oxidative stress in bone remodeling: role of antioxidants. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 209.	1.0	467
105	The use of cholecalciferol in patients with hip fracture. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 48.	1.0	7
106	The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 123.	1.0	11
107	Human Adipose Tissue-Derived Stem Cells and a Poly(ϵ -Caprolactone) Scaffold Produced by Computer-Aided Wet Spinning for Bone Tissue Engineering. Journal of Biomaterials and Tissue Engineering, 2017, 7, 622-633.	0.0	9
108	Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas. American Journal of Translational Research (discontinued), 2017, 9, 1743-1753.	0.0	19

#	ARTICLE	IF	CITATIONS
109	Epigenetic Mechanisms in Bone Biology and Osteoporosis: Can They Drive Therapeutic Choices?. International Journal of Molecular Sciences, 2016, 17, 1329.	1.8	87
110	An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells. Molecular BioSystems, 2016, 12, 1922-1928.	2.9	13
111	Natpara for the treatment of hypoparathyroidism. Expert Opinion on Biological Therapy, 2016, 16, 1417-1424.	1.4	25
112	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	1.8	151
113	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis"From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	1.6	203
114	Management of Hypoparathyroidism: Summary Statement and Guidelines. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2273-2283.	1.8	303
115	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	1.4	91
116	Effects of Dairy Products Consumption on Health: Benefits and Beliefs" A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 2016, 98, 1-17.	1.5	210
117	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine, 2016, 52, 495-506.	1.1	40
118	Fracture prevention service to bridge the osteoporosis care gap. Clinical Interventions in Aging, 2015, 10, 1035.	1.3	35
119	In Vitro Behavior of Human Adipose Tissue-Derived Stem Cells on Poly(ϵ -caprolactone) Film for Bone Tissue Engineering Applications. BioMed Research International, 2015, 2015, 1-12.	0.9	13
120	In Vitro Effects of Strontium on Proliferation and Osteoinduction of Human Preadipocytes. Stem Cells International, 2015, 2015, 1-12.	1.2	42
121	Bone status in genetic syndromes: A review. Hormones, 2015, 14, 19-31.	0.9	15
122	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine, 2015, 50, 12-26.	1.1	53
123	Massive intrathoracic lipoma in men1 syndrome. International Journal of Surgery Case Reports, 2015, 6, 247-250.	0.2	4
124	Glutathione, N-acetylcysteine and Lipoic Acid Down-Regulate Starvation-Induced Apoptosis, RANKL/OPG Ratio and Sclerostin in Osteocytes: Involvement of JNK and ERK1/2 Signalling. Calcified Tissue International, 2015, 96, 335-346.	1.5	62
125	The calcium-sensing receptor in bone metabolism: from bench to bedside and back. Osteoporosis International, 2015, 26, 2055-2071.	1.3	75
126	Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone, 2015, 79, 143-149.	1.4	42

#	ARTICLE	IF	CITATIONS
127	Taxonomy of rare genetic metabolic bone disorders. <i>Osteoporosis International</i> , 2015, 26, 2529-2558.	1.3	31
128	Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 577-593.	1.8	41
129	Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset. <i>Osteoporosis International</i> , 2015, 26, 2695-2702.	1.3	15
130	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11
131	Rare causes of osteoporosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 151-6.	1.0	36
132	A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. <i>European Journal of Endocrinology</i> , 2014, 171, K7-K17.	1.9	52
133	Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin. <i>Pediatric Rheumatology</i> , 2014, 12, 47.	0.9	9
134	Comparison of bone mass and quality determinants in adolescents and young adults with juvenile systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA). <i>Lupus</i> , 2014, 23, 1392-1406.	0.8	7
135	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 253-263.	1.6	414
136	Gaucher Disease and Bone Manifestations. <i>Calcified Tissue International</i> , 2014, 95, 477-494.	1.5	53
137	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3561-3569.	1.8	1,277
138	The role of the orthopaedic surgeon in the prevention of refracture in patients treated surgically for fragility hip and vertebral fracture. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2014, 11, 31-5.	1.0	4
139	Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. <i>Current Medical Research and Opinion</i> , 2013, 29, 1565-1572.	0.9	19
140	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 275-283.	5.5	244
141	Calcium sensing receptor signalling in physiology and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1732-1744.	1.9	123
142	The Regulatory Network Menin-MicroRNA 26a As a Possible Target for RNA-Based Therapy of Bone Diseases. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 103-108.	2.0	35
143	Hypoparathyroidism: the hormone replacement therapy is close. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 255-257.	1.2	1
144	Estrogens and melanoma: an important clinical question. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 587-588.	1.2	0

#	ARTICLE	IF	CITATIONS
145	When the government actively faces the burden of osteoporosis: the Italian experience. Archives of Osteoporosis, 2012, 7, 21-24.	1.0	1
146	Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?. Clinics, 2012, 67, 141-144.	0.6	41
147	Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2990-3011.	1.8	1,127
148	The Negative Feedback-Loop between the Oncomir Mir-24-1 and Menin Modulates the Men1 Tumorigenesis by Mimicking the "Knudson's Second Hit". PLoS ONE, 2012, 7, e39767.	1.1	81
149	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research, 2011, 26, 2317-2337.	3.1	485
150	An overview of osteoporosis: from genetics to clinics. Aging Clinical and Experimental Research, 2011, 23, 3-5.	1.4	8
151	Genetics of hypoparathyroidism and pseudohypoparathyroidism. Journal of Endocrinological Investigation, 2011, 34, 27-34.	1.8	6
152	The gaps between patient and physician understanding of the emotional and physical impact of osteoporosis. Archives of Osteoporosis, 2010, 5, 145-153.	1.0	10
153	Hyperparathyroidism in MEN1 syndrome: time to operate?. Nature Reviews Endocrinology, 2010, 6, 604-605.	4.3	1
154	Pharmacogenetics of osteoporosis. Expert Review of Endocrinology and Metabolism, 2010, 5, 905-910.	1.2	1
155	Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes. Clinical Cases in Mineral and Bone Metabolism, 2010, 7, 243-50.	1.0	14
156	Current treatment approaches for Paget's Disease of Bone. Discovery Medicine, 2010, 10, 209-12.	0.5	6
157	Microarchitecture, the key to bone quality. Rheumatology, 2009, 48, iv3-iv8.	0.9	147
158	Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. Cancer Genetics and Cytogenetics, 2009, 195, 75-79.	1.0	14
159	Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors. Genetics in Medicine, 2009, 11, 825-835.	1.1	89
160	Advances in the management of asymptomatic hyperparathyroidism. F1000 Medicine Reports, 2009, 1, .	2.9	0
161	Osteogenic Differentiation of Human Adipose Tissue-Derived Stem Cells Is Modulated by the miR-26a Targeting of the SMAD1 Transcription Factor. Journal of Bone and Mineral Research, 2008, 23, 287-295.	3.1	333
162	The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis. Journal of Endocrinological Investigation, 2008, 31, 905-909.	1.8	7

#	ARTICLE	IF	CITATIONS
163	Phosphatonins: new hormones that control phosphorus homeostasis. Expert Review of Endocrinology and Metabolism, 2008, 3, 513-526.	1.2	1
164	Genetics and pharmacogenetics of estrogen response. Expert Review of Endocrinology and Metabolism, 2007, 2, 503-516.	1.2	3
165	Role of observational studies in assessing osteoporosis therapies: the REAL study. Clinical Cases in Mineral and Bone Metabolism, 2007, 4, 161-2.	1.0	0
166	What Is the Relationship Between Paget's Disease of Bone and Hyperparathyroidism?. Journal of Bone and Mineral Research, 2006, 21, P69-P74.	3.1	13
167	MEN1 family with a novel frameshift mutation. Journal of Endocrinological Investigation, 2006, 29, 450-456.	1.8	9
168	Pancreatectomy in Multiple Endocrine Neoplasia Type 1-Related Gastrinomas and Pancreatic Endocrine Neoplasias. Annals of Surgery, 2006, 244, 61-70.	2.1	131
169	Vascular Biology and the Skeleton. Journal of Bone and Mineral Research, 2006, 21, 183-192.	3.1	267
170	Genetics of Primary Hyperparathyroidism. Urologia Internationalis, 2004, 72, 11-16.	0.6	18
171	Calcaneal quantitative ultrasound as a reliable tool in assessing osteoporosis and its risk factors in a large cohort of the Italian population. Clinical and Experimental Rheumatology, 2004, 22, 553.	0.4	0
172	Management of post-menopausal osteoporosis: Something new on the horizon?. Journal of Endocrinological Investigation, 2003, 26, 170-173.	1.8	6
173	Microencapsulation of Human Parathyroid Cells: An <i>in Vitro</i> Study. Journal of Surgical Research, 2001, 96, 81-89.	0.8	24
174	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	1,782
175	MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. European Journal of Endocrinology, 2000, 142, 131-137.	1.9	42
176	Characterization, regulation, and function of specific cell membrane receptors for insulin-like growth factor I on bone endothelial cells. Journal of Bone and Mineral Research, 1994, 9, 329-337.	3.1	53
177	Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). American Journal of Human Genetics, 1993, 53, 1167-72.	2.6	27
178	Genetic models for parathyroid tumorigenesis. Journal of Endocrinological Investigation, 1992, 15, 113-9.	1.8	1
179	Functional epithelial cell line cloned from rat parathyroid glands.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3269-3273.	3.3	58